Logo.png
CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials
11 juin 2024 09h00 HE | CanaQuest Medical Corp.
Appointee, formerly with GW Pharma (subsidiary), brings extensive expertise in cannabinoid therapeutics, including the FDA-approved launch of cannabidiol (Epidiolex®) TORONTO, ON, June 11, 2024 ...
Qualigen-Logo-Tag.png
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
12 déc. 2022 08h30 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen-Logo-Tag.png
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
15 nov. 2022 07h30 HE | Qualigen Therapeutics, Inc.
Q3 2022 FastPack ® sales increased approximately 25% year-over-yearCompany continues to execute on and advance core therapeutic programs CARLSBAD, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen...
AR_Logo_tm-021.jpg
Life Sciences Market Growth & Share by 2029 | Company Profiles, Top Regions, Latest Technology, Investment Opportunities, Future Trends | Sales, Price, Revenue, Gross Margin, Cost Analysis
15 nov. 2022 01h34 HE | Absolute Reports Pvt Ltd
Pune, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Life Sciences market report is knowledge and experience shared by industry experts to take correct decisions for manufacturers, new entrants, and industry...
1
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
19 oct. 2022 09h00 HE | Qualigen Therapeutics, Inc.
Fourth RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
Qualigen-Logo-Tag.png
Qualigen Therapeutics to Present at LD Micro Main Event XV
18 oct. 2022 09h00 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen-Logo-Tag.png
Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium
06 oct. 2022 08h00 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen-Logo-Tag.png
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
20 mai 2022 09h15 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen-Logo-Tag.png
Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®
05 avr. 2022 09h15 HE | Qualigen Therapeutics, Inc.
Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
Logo.png
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
02 févr. 2022 08h00 HE | BioRestorative Therapies, Inc
Notice of Allowance Grants Protection for Generating Implantable Three-Dimensional Scaffolds MELVILLE, N.Y., Feb. 02, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...